| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.CLPT.2006.05.008 |
| P698 | PubMed publication ID | 16952487 |
| P2093 | author name string | Graham Lappin | |
| R Colin Garner | |||
| Ajai Chaudhary | |||
| Malcolm Rowland | |||
| Berend Oosterhuis | |||
| Roeline Jochemsen | |||
| Johannes Kneer | |||
| Wilhelm Kuhnz | |||
| Willem Jan Drijfhout | |||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pharmacokinetics | Q323936 |
| P304 | page(s) | 203-215 | |
| P577 | publication date | 2006-09-01 | |
| P1433 | published in | Clinical Pharmacology & Therapeutics | Q1101529 |
| P1476 | title | Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs | |
| P478 | volume | 80 |
| Q26801794 | 68Ga-Based radiopharmaceuticals: production and application relationship |
| Q46255567 | A Human Microdose Study of the Anti-Malarial GSK3191607 in Healthy Volunteers. |
| Q86393023 | A Novel Double-Tracer Technique to Characterize Absorption, Distribution, Metabolism and Excretion (ADME) of [14C]Tofogliflozin After Oral Administration and Concomitant Intravenous Microdose Administration of [13C]Tofogliflozin in Humans |
| Q95851906 | A Review on: Phase '0' Clinical Trials or Exploratory Investigational New Drug |
| Q42585832 | A combined accelerator mass spectrometry-positron emission tomography human microdose study with 14C- and 11C-labelled verapamil. |
| Q84146544 | A highly sensitive LC‐MS/MS method capable of simultaneously quantitating celiprolol and atenolol in human plasma for a cassette cold‐microdosing study |
| Q35131936 | A microdosing approach for characterizing formation and repair of carboplatin-DNA monoadducts and chemoresistance |
| Q48025123 | A nanogram dose of the CYP3A probe substrate midazolam to evaluate drug interactions. |
| Q37173944 | A pharmacokinetic evaluation of five H(1) antagonists after an oral and intravenous microdose to human subjects |
| Q81752830 | A testing approach based on tiny doses still awaits big results |
| Q37340474 | Absolute bioavailability of evacetrapib in healthy subjects determined by simultaneous administration of oral evacetrapib and intravenous [(13) C8 ]-evacetrapib as a tracer |
| Q37810235 | Accelerator mass spectrometry best practices for accuracy and precision in bioanalytical (14)C measurements |
| Q82083203 | Accelerator mass spectrometry measurement of intracellular concentrations of active drug metabolites in human target cells in vivo |
| Q28752246 | Accelerator mass spectrometry targets of submilligram carbonaceous samples using the high-throughput Zn reduction method |
| Q33819361 | Accelerator mass spectrometry-enabled studies: current status and future prospects |
| Q92424036 | Advances in GLP-1 receptor targeting radiolabeled agent development and prospective of theranostics |
| Q36942970 | Alzheimer's disease drug development in 2008 and beyond: problems and opportunities |
| Q37363992 | Alzheimer's disease drug development: old problems require new priorities |
| Q28710144 | Animal models and conserved processes |
| Q38527478 | Approaches to intravenous clinical pharmacokinetics: Recent developments with isotopic microtracers |
| Q36953094 | Approaches using molecular imaging technology — use of PET in clinical microdose studies |
| Q37863679 | Assays and applications in warfarin metabolism: what we know, how we know it and what we need to know |
| Q53384595 | Assessment of pharmacokinetic proportionality of levofloxacin and cyclosporine over a 100-fold dose range in healthy human volunteers |
| Q38102700 | Biological and biomedical 14C-accelerator mass spectrometry and graphitization of carbonaceous samples |
| Q56430923 | Biomedical accelerator mass spectrometry: recent applications in metabolism and pharmacokinetics |
| Q36432228 | Biphasic elimination of tenofovir diphosphate and nonlinear pharmacokinetics of zidovudine triphosphate in a microdosing study |
| Q38903289 | CYP3A4 Activity is Markedly Lower in Patients with Crohn's Disease |
| Q34918079 | Carbon Isotopes Profiles of Human Whole Blood, Plasma, Red Blood Cells, Urine and Feces for Biological/Biomedical 14C-Accelerator Mass Spectrometry Applications |
| Q51521654 | Case studies addressing human pharmacokinetic uncertainty using a combination of pharmacokinetic simulation and alternative first in human paradigms |
| Q84551980 | Challenges in sexual medicine |
| Q83800986 | Clinical Relevance of Liquid Chromatography Tandem Mass Spectrometry as an Analytical Method in Microdose Clinical Studies |
| Q43998919 | Clinical relevance of predictive physiologically based pharmacokinetic methods |
| Q30593572 | Comprehensive assessment of human pharmacokinetic prediction based on in vivo animal pharmacokinetic data, part 1: volume of distribution at steady state. |
| Q30593578 | Comprehensive assessment of human pharmacokinetic prediction based on in vivo animal pharmacokinetic data, part 2: clearance. |
| Q53142573 | Cost-effectiveness Analysis of Microdose Clinical Trials in Drug Development |
| Q33664945 | Directly Coupled High-Performance Liquid Chromatography–Accelerator Mass Spectrometry Measurement of Chemically Modified Protein and Peptides |
| Q35122440 | Dose selection method for pharmacokinetic study in hemodialysis patients using a subpharmacological dose: oseltamivir as a model drug |
| Q91584992 | Dose-linearity of the pharmacokinetics of an intravenous [14 C]midazolam microdose in children |
| Q37550548 | Drug metabolism and pharmacokinetics |
| Q37810234 | Early Human ADME Using Microdoses and Microtracers: Bioanalytical Considerations |
| Q37830900 | Ethical, legal, and social implications (ELSI) of microdose clinical trials |
| Q37030959 | Ethics at phase 0: clarifying the issues |
| Q42679469 | European Bioanalysis Forum Recommendation: Scientific Validation of Quantification by Accelerator Mass Spectrometry |
| Q41083360 | Good manufacturing practice production of [(68)Ga]Ga-ABY-025 for HER2 specific breast cancer imaging |
| Q41880361 | Human absorption, distribution, metabolism and excretion properties of drug molecules: a plethora of approaches |
| Q41906250 | Human microdose evaluation of the novel EP1 receptor antagonist GSK269984A |
| Q52689111 | Impact of target interactions on small-molecule drug disposition: an overlooked area |
| Q37037370 | Innovative early development regulatory approaches: expIND, expCTA, microdosing |
| Q33340778 | Intracavity optogalvanic spectroscopy. An analytical technique for 14C analysis with subattomole sensitivity |
| Q48092928 | Mechanisms of Pharmacokinetic Enhancement Between Ritonavir and Saquinavir; Micro/Small Dosing Tests Using Midazolam (CYP3A4), Fexofenadine (p‐Glycoprotein), and Pravastatin (OATP1B1) as Probe Drugs |
| Q42837250 | Microdose Study of 14C-Acetaminophen With Accelerator Mass Spectrometry to Examine Pharmacokinetics of Parent Drug and Metabolites in Healthy Subjects |
| Q50945806 | Microdose pharmacogenetic study of 14C-tolbutamide in healthy subjects with accelerator mass spectrometry to examine the effects of CYP2C9∗3 on its pharmacokinetics and metabolism |
| Q43067629 | Microdose study of a P-glycoprotein substrate, fexofenadine, using a non-radioisotope-labelled drug and LC/MS/MS. |
| Q84142690 | Microdosing Clinical Study: Pharmacokinetic, Pharmacogenomic (SLCO2B1), and Interaction (Grapefruit Juice) Profiles of Celiprolol Following the Oral Microdose and Therapeutic Dose |
| Q37701128 | Microdosing and Other Phase 0 Clinical Trials: Facilitating Translation in Drug Development. |
| Q35940544 | Microdosing and drug development: past, present and future |
| Q46031834 | Microdosing assessment to evaluate pharmacokinetics and drug metabolism in rats using liquid chromatography-tandem mass spectrometry. |
| Q41078590 | Microdosing of a Carbon-14 Labeled Protein in Healthy Volunteers Accurately Predicts Its Pharmacokinetics at Therapeutic Dosages |
| Q91860200 | Microdosing psychedelics: More questions than answers? An overview and suggestions for future research |
| Q37964571 | Microdosing studies using accelerated mass spectrometry as exploratory investigational new drug trials |
| Q30559553 | Microdosing: A Critical Assessment of Human Data |
| Q37810137 | Microdosing: A Valuable Tool for Accelerating Drug Development and The Role of Bioanalytical Methods in Meeting The Challenge |
| Q37810237 | Microdosing: Current and The Future |
| Q42124658 | Microdosing: concept, application and relevance |
| Q35023726 | Midazolam microdose to determine systemic and pre-systemic metabolic CYP3A activity in humans |
| Q30623699 | Modeling of PET data in CNS drug discovery and development |
| Q37897477 | New era for drug discovery and development in renal disease |
| Q37810198 | New ultrasensitive detection technologies and techniques for use in microdosing studies |
| Q84472792 | Nonlinear Pharmacokinetics of Oral Quinidine and Verapamil in Healthy Subjects: A Clinical Microdosing Study |
| Q79448413 | Nontraditional approaches to first-in-human studies to increase efficiency of drug development: will microdose studies make a significant impact? |
| Q52633434 | Novel Application of the Two-Period Microtracer Approach to Determine Absolute Oral Bioavailability and Fraction Absorbed of Ertugliflozin |
| Q37846274 | Novel strategies for microdose studies using non-radiolabeled compounds |
| Q35846147 | Observational infant exploratory [(14)C]-paracetamol pharmacokinetic microdose/therapeutic dose study with accelerator mass spectrometry bioanalysis |
| Q38017723 | Ontogeny of oral drug absorption processes in children |
| Q34422598 | Pediatric microdose study of [(14)C]paracetamol to study drug metabolism using accelerated mass spectrometry: proof of concept |
| Q39907123 | PhRMA survey on the conduct of first-in-human clinical trials under exploratory investigational new drug applications |
| Q36438116 | Pharmacokinetic studies in infants using minimal-risk study designs |
| Q40031747 | Phase 0 - Microdosing strategy in clinical trials |
| Q34941964 | Phase 0 clinical trials in oncology new drug development |
| Q37184280 | Phase 0 clinical trials: conceptions and misconceptions |
| Q33985780 | Phase 0 clinical trials: recommendations from the Task Force on Methodology for the Development of Innovative Cancer Therapies |
| Q34802510 | Phase 0 trials: expediting the development of chemoprevention agents |
| Q99234124 | Phase 0/microdosing approaches: time for mainstream application in drug development? |
| Q42632997 | Phase I/II clinical safety studies of terameprocol vaginal ointment |
| Q38937832 | Phase-0/microdosing studies using PET, AMS, and LC-MS/MS: a range of study methodologies and conduct considerations. Accelerating development of novel pharmaceuticals through safe testing in humans - a practical guide. |
| Q36204764 | Physiologically-based pharmacokinetic modeling of target-mediated drug disposition of bortezomib in mice |
| Q39853044 | Population Pharmacokinetic/Pharmacodynamic Model of Subcutaneous Adipose 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD1) Activity After Oral Administration of AMG 221, a Selective 11β-HSD1 Inhibitor |
| Q33748891 | Practical Experience of Using Human Microdosing with AMS Analysis to Obtain Early Human Drug Metabolism and PK Data |
| Q45348533 | Predicting drug candidate victims of drug-drug interactions, using microdosing |
| Q37435222 | Prospective of ⁶⁸Ga-radiopharmaceutical development |
| Q48194386 | Quantification of femtomolar concentrations of the CYP3A substrate midazolam and its main metabolite 1'-hydroxymidazolam in human plasma using ultra performance liquid chromatography coupled to tandem mass spectrometry. |
| Q37803359 | Quantitative clinical pharmacology is transforming drug regulation |
| Q37981717 | Radiolabeled Absorption, Distribution, Metabolism, and Excretion Studies in Drug Development: Why, When, and How? |
| Q37266360 | Recent advances in biomedical applications of accelerator mass spectrometry |
| Q47915243 | Response to "can CYP3A activity be evaluated for drug interaction using a nanogram dose of probe drug?": evaluation of CYP3A activity with microdoses of midazolam. |
| Q34348727 | Salvage of oxidized guanine derivatives in the (2'-deoxy)ribonucleotide pool as source of mutations in DNA. |
| Q53099174 | Selected scientific topics of the 11th International Isotope Symposium on the Synthesis and Applications of Isotopes and Isotopically Labeled Compounds |
| Q42807076 | Sensitivity and Proportionality Assessment of Metabolites from Microdose to High Dose in Rats Using LC–MS/MS |
| Q43244925 | Simultaneous oral therapeutic and intravenous ¹⁴C-microdoses to determine the absolute oral bioavailability of saxagliptin and dapagliflozin |
| Q47684029 | Simultaneous pharmacokinetics evaluation of human cytochrome P450 probes, caffeine, warfarin, omeprazole, metoprolol and midazolam, in common marmosets (Callithrix jacchus). |
| Q38452569 | Small-molecule compounds exhibiting target-mediated drug disposition - A case example of ABT-384. |
| Q41456437 | Successful Use of [14C]Paracetamol Microdosing to Elucidate Developmental Changes in Drug Metabolism |
| Q26866469 | The Nuremberg Code subverts human health and safety by requiring animal modeling |
| Q39476375 | The Prediction of the Relative Importance of CYP3A/P-glycoprotein to the Nonlinear Intestinal Absorption of Drugs by Advanced Compartmental Absorption and Transit Model |
| Q38597205 | The application of human phase 0 microdosing trials: A systematic review and perspectives |
| Q37577775 | The challenge of pain management in patients with myasthenia gravis. |
| Q50654753 | The expanding utility of microdosing |
| Q36611045 | The impact of FDA and EMEA guidelines on drug development in relation to Phase 0 trials |
| Q94664363 | The oral bioavailability and metabolism of midazolam in stable critically ill children: a pharmacokinetic microtracing study |
| Q50871327 | To Apply Microdosing or Not? Recommendations to Single Out Compounds with Non-Linear Pharmacokinetics |
| Q53260626 | Trends in Microdosing and Other Exploratory Human Pharmacokinetic Studies for Early Drug Development |
| Q28818313 | Use of Accelerator Mass Spectrometry in Human Health and Molecular Toxicology |
| Q34596727 | Use of microdosing and accelerator mass spectrometry to evaluate the pharmacokinetic linearity of a novel tricyclic GyrB/ParE inhibitor in rats |
Search more.